Adhaere Pharmaceuticals, Inc is a new, privately held, company developing novel small molecule therapeutics for the treatment of cancer and inflammatory and autoimmune diseases. The company's innovative approach focuses on a unique way of targeting adhesion receptors on leukocytes. Adhaere has also created a broadly applicable proprietary technology platform for the discovery of a pipeline of novel therapeutics.